- Reaction score
- 1,703
Trials of a new HIV vaccine have begun at Oxford University, building on the success of the Covid vaccine developed by the institution.
It is the first in a series of evaluations in HIV-negative individuals, for prevention, and in people living with HIV, for a cure.
In phase one of the trial, which is run by the university's Jenner institute, 13 HIV-negative adults, aged 18-65 and who are considered not to be at high risk of infection, will initially receive one dose of the HIV vaccine. A further booster dose will be given after four weeks.
HIV-positive adults will be involved in later phases of the trial, while plans exist to start similar trials in Europe, Africa and the US.
The trial is part of the European Aids Vaccine Initiative, an internationally collaborative research project funded by the European Commission.
www.itv.com
It is the first in a series of evaluations in HIV-negative individuals, for prevention, and in people living with HIV, for a cure.
In phase one of the trial, which is run by the university's Jenner institute, 13 HIV-negative adults, aged 18-65 and who are considered not to be at high risk of infection, will initially receive one dose of the HIV vaccine. A further booster dose will be given after four weeks.
HIV-positive adults will be involved in later phases of the trial, while plans exist to start similar trials in Europe, Africa and the US.
The trial is part of the European Aids Vaccine Initiative, an internationally collaborative research project funded by the European Commission.
Trials of new HIV vaccine begin at Oxford University | ITV News
It is the first in a series of evaluations in HIV-negative individuals, for prevention, and in people living with HIV, for a cure. | ITV National News
www.itv.com
Last edited by a moderator:
